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The concept of metabolic modulation in acute myocardial infarction (AMI) with glucose-insulin-potassium (GIK) 
infusion was initially proposed in the 1960s as a means of pro-
ducing electrical stability in the myocardium during episodes of 
ischemia (1). Subsequently, it was proposed that GIK therapy 
provided metabolic support to ischemic myocardium. During 
episodes of cardiac ischemia, the myocardium converts from 
aerobic carbohydrate metabolism to anaerobic free fatty acid 
metabolism, which results in the production of metabolites and 
free radicals that are toxic to the myocardium, and are associ-
ated with ventricular arrhythmias (2) and decreased myocar-
dial contractility (3). It was hypothesized that insulin and 
glucose infused as part of GIK therapy resulted in a shift from 
potentially harmful free fatty acid metabolism to glucose 
metabolism in the ischemic myocardium. Furthermore, sup-
pression of plasma free fatty acid levels by insulin would further 
facilitate this effect (4). It is now more than 10 years since we 
published our meta-analysis evaluating the role GIK therapy 
on mortality after AMI (5), in which a total of 1932 patients 
from nine trials were evaluated. We demonstrated that the 
number of deaths was significantly lower in patients who 
received GIK (16.1%) than in patients who received placebo 
(21%). Based on the results of this meta-analysis, we concluded 
that GIK therapy most likely had a role in reducing in-hospital 
mortality following AMI. In our original meta-analysis, we 
argued that there was a need for a larger randomized trial to 
investigate the role of GIK as an adjunct to thrombolysis or 
primary percutaneous coronary intervention following AMI on 
mortality. Since then, many larger randomized trials investigat-
ing the role of GIK in the setting of AMI have been published. 
The Glucose-Insulin-Potassium Study-I (GIPS-I) (6) showed 
clinical benefit of GIK in ST segment elevation myocardial 
infarction (STEMI) patients without signs of heart failure; 
however, GIPS-II (7) could not confirm this finding. Two other 
recent large sample trials – the Clinical Trial of Reviparin and 
Metabolic Modulation in Acute Myocardial Infarction 
Treatment (CREATE)-Estudios Cardiologicos Latinoamerica 
(ECLA)-II (8), which included more than 20,000 patients, 
and the Polish-Glucose-Insulin-Potasium trial (Pol-GIK) (9) 
trial comprising close to 1000 patients – showed no beneficial 
effects from GIK therapy. Although The Organization for the 
Assessment of Strategies for Ischemic Syndromes (OASIS-6) 
trial (10), a large, multicentre, randomized trial, was stopped 
prematurely after the enrollment of 2748 patients following 
publication of CREATE-ECLA II, it did not show any benefit 
from GIK therapy. We have therefore updated our meta-analysis 
to include these more recent trial data.
Methods
A MEDLINE search (1996 to February 2008) was performed 
using the search term “myocardial infarction” or “AMI” and a 
set of terms for GIK including “glucose”, “insulin”, “glucose-
insulin”, “GIK”, “GIP”, “PGI”, “glucose-insulin-potassium” and 
“metabolic support”. Furthermore, references and review articles 
obtained in this manner were scrutinized to ensure that all rel-
evant studies were identified. Only controlled studies that docu-
mented 30-day mortality rates and were properly randomized 
were selected. Studies that were published before 1996 were the 
subject of the previous meta-analysis (5), and these studies were 
also included in the current meta-analysis. Studies were excluded 
if they used inadequate means of randomization, such as alloca-
tions based on date of birth, alternate numbers, admission to a 
particular unit or date of presentation. Trials that used retro-
spective group or historic cases as a control group, and those that 
limited the study to a particular subgroup were also excluded. 
Only trial-level data were used for the present meta-analysis.
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BACkgrouNd: Glucose-insulin-potassium (GIK) therapy has been 
proposed to provide metabolic support to ischemic myocardium. A meta-
analysis that included 1932 patients performed 10 years previously demon-
strated that GIK therapy may have an important role in reducing mortality 
after acute myocardial infarction (AMI). Since then, many larger random-
ized trials investigating the role of GIK in the setting of AMI have been 
published; hence, the present study repeats the previous meta-analysis 
performed by the current authors to include these trials.
Method ANd resuLts: A systematic MEDLINE search for all ran-
domized, placebo-controlled studies of GIK therapy in the setting of AMI 
was conducted and a meta-analysis of the mortality data was performed. 
A total of 16 randomized trials from 1966 to 2008 were identified, with 
28,374 patients included in the current meta-analysis. There was a total of 
1367 deaths (9.6%) in the GIK group, with 1351 deaths (9.6%) in the 
control group. Meta-analysis did not reveal any benefit from GIK treat-
ment (OR 1.0; 95% CI 0.9 to 1.1; P=0.9). Subgroup analysis of patients 
given high-dose GIK and in patients in whom reperfusion was not obtained 
did not demonstrate a benefit from GIK therapy.
CoNCLusioN: A meta-analysis of 16 randomized trials that spanned 
40 years and involved more than 28,000 patients did not reveal any mor-
tality benefit for ST segment elevation AMI using GIK therapy when data 
from the modern thrombolysis/primary percutaneous coronary interven-
tion era were included. 
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statistical analysis
For individual trials, the c2 heterogeneity test (11) was used to 
calculate the significance, ORs and 95% CIs for the differences 
in mortality between the GIK and placebo group, except for 
trials in which the expected number of deaths was less than 
five. For trials in which the number of deaths was less than five, 
the Fisher’s exact test was used (12). Statistical analysis was 
performed using Arcus Quickstat (Research Solutions, United 
Kingdom).
resuLts
Since the original meta-analysis (5), a total of nine trials 
(6-10,13-16) were identified, of which seven (6-10,15,16) were 
included in the current analysis (Table 1). Two trials (13,14) 
were excluded because only diabetic patients were enrolled in the 
Diabetes Mellitus, Insulin-Glucose Infusion in Acute Myocardial 
Infarction (DIGAMI-2) trial (13) and only patients who were dia-
betic or presented with hyperglycemia were included in the other 
study (14). Similar exclusion criteria were applied in the original 
meta-analysis (5) in which the DIGAMI-1 trial was excluded for 
the same reason. Studies that were conducted between 1998 and 
2005, and those included in the present meta-analysis were open 
design. Delays between the onset of chest pain and treatment var-
ied from less than 12 h to less than 48 h, with treatment duration 
of between 12 h and 24 h in all studies. All trials reported 30-day 
mortality. A total of 26,442 patients were included in the current 
meta-analysis, with 13,293 patients in the GIK treatment group 
and 13,149 patients in the control group. Mortality rates for the 
control group and GIK treatment group for the individual trials are 
presented in Table 2. Pooled data demonstrate that the total num-
ber of deaths was 1213 (9.1%) in the GIK group and 1146 (8.7%) 
in the control group. GIK treatment did not significantly influ-
ence 30-day mortality post-AMI (OR 1.05; 95% CI 0.97 to 1.14; 
P=0.34) (Figure 1). Summation of these new data to the original 
meta-analysis data performed by Fath-Ourdoubadi and Beatt (5) 
on nine randomized trials (17-25) resulted in a total of 16 trials 
and 28,374 patients, with a total mortality of 1367 (9.6%) in the 
GIK group and 1351 (9.6%) in the control group. A repeat meta-
analysis of these 16 randomized trials did not significantly alter the 
outcome (OR 1.0; 95% CI 0.9 to 1.1; P=0.9) (Figure 2).
Most of the trial data analyzed in the Fath-Ourdoubadi and 
Beatt (5) meta-analysis were from an era when thrombolysis 
or primary percutaneous coronary intervention was not per-
formed; therefore, the patients included in the present meta-
analysis would represent AMI in which no reperfusion was 
achieved (with the exception of the study by Satler et al [25]). 
Consequently, the data from 1966 to 2007 were re-analyzed in 
the patient cohort in which reperfusion was not achieved to 
determine whether this influenced outcome. Studies in which 
reperfusion strategies were not used (16-23) and current studies 
(6,8,16) in which mortality data was presented in the nonreper-
fusion subgroup, were pooled. Analysis was performed on a total of 
5716 patients, with 437 (15%) deaths in the GIK treatment group 
and 467 (16.4%) deaths in the control group. Figure 3 illustrates 
that no significant benefit was observed with GIK treatment in 
this subgroup (OR 0.92; 95% CI 0.80 to 1.06; P=0.27). 
Finally, data were pooled from the trials in which high-dose 
GIK solution was used (6-8,15,22-25). A total of 25,369 patients 
were included in the meta-analysis (Figure 4). A mortality of 
9.1% was observed in the high-dose GIK group and 9.1% in 
TABLE 1
Design of the randomized placebo-controlled trials of glucose-insulin-potassium (GIK) therapy in acute myocardial 
infarction (AMI)
Study (ref) Year Design (n)
Delay between onset of 





ECLA pilot  
   (16)
1998 Randomized, controlled, open (407) <24 h Severe renal impairment, hyperkalemia High and  
   low dose
24 h
Pol-GIK (9) 1999 Prospective, randomized  
   placebo-controlled, open (954)
<24 h Pulmonary congestion, renal failure,  
diabetes requiring insulin
Low dose 24 h
GIPS-I (6) 2003 Randomized, open (940) <24 h Thrombolysis, poor life expectancy High dose 12 h
Pache et al  
   (15)
2004 Randomized, open (312) <48 h NA High dose 24 h
ECLA (8) 2005 Randomized, controlled, open  
   (20,201)
<12 h Type 1 diabetes mellitus, renal  
impairment, hyperkalemia
High dose 24 h
GIPS-II (7) 2006 Randomized, controlled (889) <24 h Pulmonary congestion High dose 12 h
OASIS-6 (10) 2007 Randomized, controlled (2748) <24 h but decreased to 
<12 h after 4300 
patients recruited
Oral anticoagulants, moderate renal 
impairment
High dose NA
ECLA Estudios Cardiologicos Latinoamerica; GIPS Glucose-Insulin-Potassium Study; NA Not available; OASIS The Organization for the Assessment of Strategies 
for Ischemic Syndromes trial; Pol-GIK Polish Glucose-Insulin-Potassium study
TABLE 2
Thirty-day mortality in randomized trials of glucose-





Deaths (at 30 days),  
n (%)
  PGIK Control GIK Control
ECLA pilot (16),  
   1998
268 139 18 (6.7) 16 (11.5) 0.1
Pol-GIK (9), 1999 494 460 44 (8.9) 22 (4.8) 0.01
GIPS-I (6), 2003 476 464 23 (4.8) 27 (5.8) 0.5
Pache et al (15),  
   2004
155 157 7 (4.5) 5 (3.2) 0.85
ECLA (8), 2005 10,088 10,107 1004 (10) 976 (9.7) 0.45
GIPS-II (7), 2006 444 445 13 (2.9) 8 (1.8) 0.26
OASIS-6 (10), 2007 1368 1377 104 (7.6) 92 (6.7) 0.76
ECLA Estudios Cardiologicos Latinoamerica; GIPS Glucose-Insulin-Potassium 
Study; OASIS The Organization for the Assessment of Strategies for Ischemic 
Syndromes trial; Pol-GIK Polish Glucose-Insulin-Potassium study
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control group, with no observed benefit of high-dose GIK infusion 
on mortality observed (OR 1.04; 95% CI 0.95 to 1.13; P=0.43).
disCussioN
It is now 10 years since our most recent meta-analysis (5) that 
included 1932 patients, in which a 28% reduction in mortality 
post-AMI was demonstrated following treatment with GIK 
(P=0.004). Since publication of this meta-analysis, many larger 
randomized controlled trials investigating the effects of GIK on 
patients with AMI have been conducted. GIPS-I (6) showed 
clinical benefit of GIK in STEMI patients without signs of 
heart failure; however, GIPS-II (7) could not confirm this find-
ing. The ECLA GIK pilot trial (16) involving 407 patients 
demonstrated a nonsignificant decrease in mortality following 
GIK therapy (6.7%) when compared with placebo (11.5%). 
Similarly, in the more recent CREATE-ECLA (8), a trial 
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Figure 1) Comparison of 30-day mortality outcome in patients 
treated with glucose-insulin-potassium (GIK) therapy. ORs and 
95% CIs are presented for individual studies and pooled data. ECLA 
Estudios Cardiologicos Latinoamerica; GIPS Glucose-Insulin-
Potassium Study; OASIS Organization for the Assessment of 
Strategies for Ischemic Syndromes trial; Pol-GIK Polish GIK trial
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Figure 2) Comparison of 30-day mortality outcome in patients 
treated with glucose-insulin-potassium (GIK) therapy. ORs and 
95% CIs are presented for individual studies and pooled data. 
ECLA Estudios Cardiologicos Latinoamerica; GIPS Glucose-
Insulin-Potassium Study; MRC Medical Research Council; 
OASIS Organization for the Assessment of Strategies for Ischemic 
Syndromes trial; Pol-GIK Polish GIK trial
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Figure 3) Comparison of 30-day mortality outcome in patients treated 
with glucose-insulin-potassium (GIK) therapy in whom reperfusion 
was not attained. ORs and 95% CIs are presented for individual stud-
ies and pooled data. ECLA Estudios Cardiologicos Latinoamerica; 
GIPS Glucose-Insulin-Potassium Study; MRC Medical Research 
Council; OASIS Organization for the Assessment of Strategies for 
Ischemic Syndromes trial
GIK better Control better
Odds ratio and 95% CI
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Figure 4) Comparison of 30-day mortality outcome in patients 
treated with high-dose glucose-insulin-potassium (GIK) therapy. 
ORs and 95% CIs are presented for individual studies and pooled 
data. ECLA Estudios Cardiologicos Latinoamerica; GIPS Glucose-
Insulin-Potassium Study; OASIS Organization for the Assessment 
of Strategies for Ischemic Syndromes trial
GIK therapy for acute myocardial infarction
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evaluating the effects of high-dose GIK on mortality in 
20,000 patients with STEMI, showed no significant difference 
in mortality. The OASIS-6 trial (10), a large, multicentre, 
randomized trial, was stopped prematurely after having enrolled 
2748 patients following publication of CREATE-ECLA; the 
OASIS-6 trial showed no benefit from GIK treatment. Our 
current meta-analysis of these more recent trials involving 
26,442 patients demonstrates no significant difference between 
mortality in the GIK treatment group and the control group, 
even if the meta-analysis is repeated to include our original 
data. 
In contrast, a recent analysis of the OASIS-6 and CREATE-
ECLA trials combined trial populations and actually demon-
strated an increased mortality associated with GIK treatment 
in the first three days. Although in agreement with our current 
data, this difference disappeared at 30 days (10). Interestingly, 
at 6 h and 24 h postrandomization, serum glucose levels were 
significantly greater in the GIK cohort than in the control 
group and, on average, the net fluid balance in the GIK cohort 
was 600 mL greater after 24 h. 
Indeed, it is well recognized that admission glucose level is 
a stronger predictor of mortality in the setting of AMI (26,27). 
Analysis by Díaz et al (10) revealed that glucose and fluid bal-
ance were independent predictors of mortality at three days. 
Once these variables were accounted for, no excess mortality 
was observed at this time point in the GIK group. Clearly, this 
is a major limitation of all GIK studies performed to date in 
that any potential benefit incurred from metabolic modulation 
within the myocardium from GIK infusion may be offset by the 
detrimental effects of hyperglycemia and increased net fluid 
balance in the GIK arm of these trials.
Our original meta-analysis showing a benefit from GIK 
therapy was performed on studies conducted in an era when 
revascularization and thrombolysis were not routinely used in 
the treatment of AMI. Therefore, it is possible that GIK ther-
apy benefits patients in whom revascularization is not achieved. 
Experimental evidence suggests a beneficial effect of GIK by 
shifting myocardial free fatty acid metabolism toward glucose 
metabolism. This consumes less oxygen and produces less toxic 
byproducts (28). Furthermore, reperfusion injury may be 
reduced by limiting apoptosis of postischemic myocardial cells. 
However, once adequate reperfusion has been established, GIK 
may be of only limited value because maximal myocardial sal-
vage has already occurred. This potential benefit of treatment 
with GIK in patients in whom reperfusion is not achieved is 
not supported by our meta-analysis – there was no improve-
ment in 30-day mortality rates post-treatment with GIK. It has 
also been argued that many trials do not show a beneficial 
effect of low-dose GIK solution on reducing mortality because 
the doses of glucose and insulin used are not sufficient to sup-
press free fatty acid levels (29). However, in the pilot ECLA 
study (16), no significant difference in mortality was observed 
between ‘low-dose’ and ‘high-dose’ GIK treatment. Indeed, our 
meta-analysis of trials that used only high-dose GIK infusion 
did not demonstrate any benefits on mortality rates.
The discrepancy in the outcome between the meta-analysis 
of nine smaller trials performed 10 years previously and the cur-
rent meta-analysis involving six significantly larger trials is dif-
ficult to explain. It may relate to a publication bias of smaller 
trials for which neutral studies are less likely to be published 
compared with similar studies with positive results. 
Furthermore, our meta-analysis is heavily weighted toward the 
CREATE-ECLA trial, which contributed 71.2% of the patients 
to the current analysis. Even when patients from the CREATE-
ECLA trial are excluded, repeat meta-analysis of the dataset 
does not show any benefit of GIK in the setting of AMI (data 
not shown).
Our original meta-analysis was performed on studies in 
which beta-blockade and antiplatelet therapy was not rou-
tinely used, resulting in an increased ischemic burden in those 
patients and a greater metabolic insult to the myocardium. 
Under these conditions, it is possible that GIK therapy has 
more of a myocardial protective role. Indeed, beta-blockade 
itself may shift metabolism from free fatty acid oxidation to 
glucose oxidation (30); therefore, its routine use in the man-
agement of AMI in the current era may reduce the benefit from 
therapies such as GIK. There is good experimental evidence 
from animal models that GIK should be given early post-AMI, 
so as to reach the ischemic myocardium before reperfusion. In 
several animal species including rat (31), baboon (32) and rab-
bit (33), GIK was protective when started only a few minutes 
after coronary ligation. It is believed that early administration 
of GIK post-AMI can slow the rate of myocardial injury during 
ischemia and, consequently, substantially increase the extent 
of myocardial salvage when effective reperfusion occurs. 
However, in these animal models of ischemia, antiplatelet 
therapy, beta-blockade and revascularization therapy are not 
used in the context of AMI; therefore, relevance to clinical 
practice remains uncertain. In the CREATE-ECLA trial (8), 
which was by far the largest overall contributor to patient num-
bers in the current meta-analysis, 83% of patients had reper-
fusion therapy at a median time of 3.85 h after symptom onset, 
and randomization to GIK or control groups occurred almost 
1 h later (median 4.7 h postsymptom onset) after which GIK 
was started mostly ‘within the next hour’ (ie, up to 2 h post 
reperfusion) (29). Importantly, these data would suggest that 
a key component of the CREATE-ECLA trial was commonly 
violated because the trial explicitly prescribed initiation of 
GIK infusion before reperfusion. Clearly, such a delayed and 
often postreperfusion administration of GIK minimized its 
potential to reduce mortality. Of note, however, in a subgroup 
analysis of OASIS-6 and CREATE ECLA, it appeared that 
time between symptom onset and randomization to a treat-
ment arm did not significantly influence outcome, even when 
symptom onset occurred at less than 2 h (10). In contrast, 
GIK infusion was started within 15 min to 20 min after admis-
sion in the GIPS-1 study (6), which was approximately 30 
min earlier than the average door to balloon time (and hence 
reperfusion) of 45 min. Interestingly, in this study, a benefit 
of GIK was demonstrated in the subgroup without signs of 
heart failure (Killip class 1), although this observation was not 
reproduced in the later GIPS-II study (7). Clearly, the timing 
of GIK in relation to reperfusion may have an important role 
in its potential for benefit. The ongoing National Institutes 
of Health-sponsored Immediate Myocardial Metabolic 
Enhancement During Initial Assessment and Treatment in 
Emergency care (IMMEDIATE) study of prehospital initiation 
of GIK therapy for acute coronary syndrome patients aims to 
address this issue (www.immediatetrial.com/). It is anticipated 
that 15,540 patients will be included in this study and the 
Mamas et al
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primary end point will be 30-day and one-year mortality. 
Secondary end points will include in-hospital cardiac arrest, 
progression of unstable angina pectoris to AMI, infarct size 
and heart failure. In contrast to other GIK trials, this trial will 
test the efficacy of GIK in all acute coronary syndromes rather 
than STEMI alone.
All GIK trials to date have investigated the role of GIK in 
STEMI. However, there are very little trial data investigating 
whether GIK plays a role in the treatment of other acute coron-
ary syndromes. Yazici et al (34) studied the effects of high-dose 
GIK in a randomized study of 52 consecutive patients presenting 
with non-STEMI who underwent percutaneous coronary inter-
vention. They demonstrated that GIK infusion initiated 24 h 
before coronary stenting for non-STEMI resulted in less myocar-
dial damage as determined by postprocedure troponin I levels. 
Clearly, the role of GIK in non-STEMI warrants further investi-
gation and it is hoped that the ongoing IMMEDIATE trial will 
provide further information regarding this issue. 
CoNCLusioNs
Our meta-analysis performed on 16 randomized trials that spanned 
more than 40 years and included more than 28,000 patients does 
not demonstrate any benefits from GIK on mortality post-ST seg-
ment elevation and does not support its use as a treatment 
strategy in AMI. Ongoing trials may clarify whether earlier 
initiation of GIK therapy is associated with benefit in acute 
coronary syndromes.
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